First Week of IMNM March 20th Options Trading

Immunome (IMNM) is highlighted for two option strategies: a sell-to-open $18 put bid at $0.10 which sets an effective purchase basis of $17.90 vs. the $22.91 market price (≈21% OTM) with a 76% chance to expire worthless and a 0.56% return (3.22% annualized) if it does. The $25 call bid at $0.70 as a covered-call on shares bought at $22.91 would yield 12.18% to be called by the March 20 expiration (3.06% boost or 17.71% annualized if it expires worthless), while implied volatilities are 138% (put) and 94% (call) versus a 12‑month trailing volatility of 78%.

Analysis

Market structure: The options flow around IMNM disproportionately benefits short-dated premium sellers and retail covered-call buyers: sellers can collect $0.10 on a Mar-20 $18 put (effective entry $17.90, ~21% OTM) or $0.70 selling a $25 call (9% OTM). High implied vols (put IV 138% vs call IV 94% vs realized 78%) show asymmetric downside fear and create elevated premia that enrichs market makers and option sellers if no binary biotech event occurs within weeks.

Risk assessment: Tail risks are classic biotech: trial failure, adverse safety readouts or a dilutive secondary could gap the stock below $15–$18 and blow out IV; low-probability but >100% downside moves possible over quarters. Immediate (days) sensitivity is to IV and press releases; short-term (weeks to Mar-20) outcomes hinge on whether the market-held probability (~24%) of assignment materializes; long-term (quarters) fundamentals and cash runway drive equity value.

Trade implications: Tactical plays favor small, income-oriented positions rather than outright directional longs. Implement cash‑secured $18 puts or covered calls to harvest elevated premia, prefer defined-risk verticals (sell $18 put / buy $15 put) to limit tail loss. Avoid naked long exposure >1–2% NAV; if long, buy protection (buy $18–20 puts or collars) when IV spikes >150%.

Contrarian angles: The market is likely overstating near-term downside if no imminent readout/secondary is scheduled; that makes short-dated skew-selling profitable but only size-limited. Historical parallels (pre-readout biotech where IV collapses if no news) suggest selling premium 7–30 days out can work, but mispricing is quickly reversed by event risk — downside underpricing is the real danger.

Key Decisions for Investors

• Establish a small (0.5–1.5% NAV) cash‑secured sell-to-open IMNM Mar-20 $18 puts at $0.10 (effective entry $17.90). Hedge by buying a Mar-20 $15 put if wanting defined risk (create 18/15 put vertical) and limit max loss; size max notional to 1.5% NAV due to biotech tail risk.
• If already long IMNM, sell-to-open Mar-20 $25 calls at $0.70 (covered call) on 1–2% NAV position to lock ~12% short-term upside to $25 and collect 3.06% premium; plan to accept assignment or roll up only if IV drops >30% or price >$26 pre-expiry.
• If pursuing volatility sell, prefer defined-risk short-dated credit spreads (sell $25 call / buy $30 call or sell $18 put / buy $15 put) sized to <1% NAV; avoid naked short vol because a binary event could spike IV >200%.
• Do NOT add >2% gross long exposure until 30–60 day window for any technical readouts or financing closes; specifically monitor SEC filings and any S-1/S-3 within 30 days and IV move >20% (action: tighten hedges if IV rises >20% or cut size if S-1 appears).